Canine malignant melanoma cells (CMM cells)

Canine malignant melanoma (CMM) cells are highly aggressive neoplastic cells derived from melanocytes, most commonly affecting the oral cavity, nail beds, and skin of dogs [5, 10]. These cells are characterized by rapid proliferation, a high propensity for metastasis, and resistance to standard radiation and chemotherapy, making them a primary challenge in veterinary oncology [2, 3]. Although 'Canine malignant melanoma cells' refers to a cell population rather than a single molecular target, they serve as the functional target for various therapeutic interventions because of their expression of specific antigens and dysregulated signaling pathways [6]. For example, the Oncept vaccine targets these cells by inducing an immune response against tyrosinase, an enzyme often overexpressed in the melanoma lineage [5]. Additionally, CMM cells frequently demonstrate overactivation of the PI3K/AKT/mTOR and MAPK/ERK pathways, which are therapeutic focal points for inhibitors like toceranib and rapamycin [1, 2, 7]. Due to their biological and genetic similarities to human mucosal melanoma, CMM cells are considered an important comparative oncology model [6, 10].

Other names

Canine oral melanoma cellsCanine mucosal melanoma cellsCMM cell linesNeoplastic canine melanocytes

Drugs targeting these cells utilize several distinct mechanisms: the Oncept vaccine induces a xenogeneic immune response against the Tyrosinase enzyme expressed by the cells [5]; small molecule inhibitors such as Toceranib target receptor tyrosine kinases including KIT and VEGFR to inhibit growth and angiogenesis [2, 4]; rapalogs like Rapamycin and Everolimus inhibit the PI3K/AKT/mTOR signaling pathway critical for cellular survival and proliferation [1, 7]; and Selective Inhibitors of Nuclear Export (SINE) like Verdinexor trap tumor suppressor proteins within the cell nucleus to induce apoptosis [2].